Earnings ·
Reports Q3 net loss of $34.2M and cash position of $315.3M
BBOTBridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics reported a third-quarter net loss of $34.2 million, or $0.43 per share, compared to a loss of $44.8 million in the prior-year period. Research and development expenses decreased to $29.6 million from $35.1 million, while general and administrative costs fell to $7.9 million from $14.1 million due to lower personnel charges. The company ended the quarter with $315.3 million in cash, equivalents, and marketable securities, providing a runway into 2029. Clinically, BBO-8520 plus pembrolizumab demonstrated a 75% objective response rate in KRAS G12C inhibitor-experienced NSCLC patients. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting RAS and PI3Kα malignancies.